January 27, 2023
Article
Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, provides a case-based perspective on the benefit of auricular acupuncture as a tool for managing cancer pain.
January 26, 2023
Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IB, II, or IIIA following resection and platinum-based chemotherapy.
Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.
Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.
January 25, 2023
Patients with breast cancer who carry BRCA1, BRCA2, CHEK2, or PALB2 germline pathogenic variants may be at a greater risk for contralateral breast cancer and may benefit from enhanced surveillance and risk-reduction strategies.
The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
January 24, 2023
The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.
January 23, 2023
Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.
January is cervical cancer awareness month. This third article in a series highlights current cervical cancer treatment options.